Molina Healthcare, Inc. (MOH) Stock: Price, Forecast & Analyst Target
Molina Healthcare, Inc. (MOH) — MoonshotScore 66/100 (Strong band), calculated Oct 26, 2026. Price $209.15 (-3.46%), as of the Oct 23, 2026 trading session; market cap $10.9B. Expected results Feb 4, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Market value / cash and short-term investments: 1.27× (market value Oct 23, 2026; cash Sep 30, 2026) · expected results Feb 4, 2027
Molina Healthcare, Inc. · MOH · NYSE · Healthcare · Medical - Healthcare Plans
Research dated 2026-09-13: Molina Healthcare is a managed-care insurer built around government-sponsored coverage, with Medicaid Solutions carrying most of the revenue base and Medicare and Marketplace adding distinct risk pools. The case depends on whether premium rates catch up with medical costs quickly enough to restore underwriting profitability without sacrificing membership and premium revenue.
Price as of Oct 23, 2026
Key Statistics
MoonshotScore v2 · Molina Healthcare (MOH)
StrongWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality, at a cheap price, but a strained balance sheet and weak growth; the market is already moving on it. Business Quality: Solid; Financial Safety: Strained; Valuation: Fair; Growth Durability: Fading; Momentum: Surging.
- quarterly revenue $10.58B (Q3 FY2026, quarter ended Sep 30, 2026)
- EPS beat 4 of 8
- Altman Z 4.12 · Piotroski F 5
Helping: business quality, an attractive price, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 66 | Strong | |
| 66 | Strong | |
| 66 | Strong | |
| 66 | Strong | |
| 64 | Fair | |
| 66 | Strong |
The score moved from 65 in the stored Oct 24, 2026 snapshot to 66 in the current publication computed Oct 26, 2026 (+1); the largest pillar moves were Growth Durability +1 and Momentum -1.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · Educational signal · not a buy or sell recommendation · How the MoonshotScore is computed →
Price & valuation
| Measure | Value |
|---|---|
| Latest provided price | $209.15 |
| Change on the day | -3.46% |
| 52-week range | $121.06–$244.89 |
| Market capitalisation | $10.9B |
| Price / earnings (trailing) | 62.37 |
| Shares traded on the day | 1.27M |
| Beta (volatility vs the S&P 500) | 0.78 |
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file or a dated event that is not a results report. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings call · management outlook
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
Management outlook
We continue to expect full year premium revenue of approximately $42 billion.
Mark Keim · Statement from
We expect the fourth quarter G&A ratio to fall below 6% due to the impact of operating leverage on the additional Florida CMS revenue and disciplined cost management.
Mark Keim · Statement from
Statement dates identify the earnings call, not a deadline. Management expectations and provider estimates can change.
Read management statementsOther perspectives
Council score for Molina Healthcare (MOH): perspectives
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
5-Factor Breakdown
Legends Council
3 lenses, 0 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Oct 14, 2026 · older than the 27 hours refresh window; not a current reading
Munger's Mindset
Balance Sheet & Valuation · historical
Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
On Sep 10, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.
Readings on this page are from Oct 27, 2026, except a card that shows its own read date.
Watch the MOH film — every key number, told as a short cinematic story
~2 min · open the film
What is Molina Healthcare (MOH), and what does it report?
Short answer · as of
Molina sells health-plan coverage chiefly to people eligible for Medicaid, Medicare, or state insurance marketplaces.
Research dated 2026-09-13.
Molina sells health-plan coverage chiefly to people eligible for Medicaid, Medicare, or state insurance marketplaces. Revenue largely represents premiums tied to covered membership; the economic result depends on what remains after members’ medical claims and administrative costs are paid.
This is not a broad commercial-benefits story. Medicaid Solutions dominates segment revenue, while Medicare and Marketplace are meaningful but much smaller, so consolidated growth can coexist with weak earnings when the cost of care rises faster than government-set premiums.
What do the latest results show for Molina Healthcare (MOH)?
Short answer · as of
The most recent reported quarter, Q3 FY2026, carried revenue of $10.58B.
Research dated 2026-09-13.
The latest reported period brought a modest sequential revenue increase and a recovery in net income and earnings per share, but operating profit weakened. The broader record is harsher: annual revenue kept rising while annual net income fell sharply, followed by a quarterly loss and only partial profitability afterward.
Management continues to frame Medicaid margins as being near a trough and expects future state rate setting to reflect more recent medical-cost experience. That is an outlook, not a completed repair. Marketplace remains another drag under management’s full-year guidance, even as the company maintained its membership and premium-revenue expectations.
Recent earnings have also been difficult to read through headline revenue alone. Revenue has often met or exceeded expectations while earnings outcomes ranged from beats to a deep miss, reinforcing that medical-cost performance matters far more than premium volume by itself.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
- Latest quarter · revenue
- $10.58B Sep 30, 2026
- Latest quarter · SG&A
- $710.00M Sep 30, 2026
- Latest quarter · FMP standardized operating result
- $106.00M Sep 30, 2026
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Sep 30, 2026 | $10.58B | Not available | $710.00M | $106.00M |
| Jun 30, 2026 | $10.87B | Not available | $724.00M | $145.00M |
| Mar 31, 2026 | $10.80B | Not available | $779.00M | $83.00M |
| Dec 31, 2025 | $11.38B | Not available | $795.00M | −$162.00M |
USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $11.08B Oct 21, 2026
- Latest report · revenue estimate
- $10.86B Oct 21, 2026
- Latest report · revenue vs estimate
- Above estimate Oct 21, 2026
- Latest report · EPS vs estimate
- Above estimate Oct 21, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Oct 21, 2026 | $11.08B | $10.86B | $0.8900 | $0.7900 |
| Jul 22, 2026 | $10.87B | $10.83B | $1.5100 | $1.3900 |
| Apr 22, 2026 | $10.80B | $10.87B | $2.3500 | $1.9000 |
| Feb 5, 2026 | $11.38B | $10.88B | −$2.7500 | $0.4300 |
Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Q3 FY2026 | $10.58B | $38M | $0.74 (diluted) |
| Q2 FY2026 | $10.87B | $60M | $1.19 (diluted) |
| Q1 FY2026 | $10.80B | $14M | $0.27 (diluted) |
| Q4 FY2025 | $11.38B | -$160M | -$2.77 (diluted) |
What are the financial strengths and risks for Molina Healthcare (MOH)?
Short answer
Cash and short-term investments were $8.58B at the Sep 30, 2026 balance-sheet date. Operating cash flow was −$159.00M for the quarter ended Sep 30, 2026, meaning operations used cash. These figures do not establish a cash runway.
Research dated 2026-09-13.
Cash and investments exceed total debt by a wide margin, and short-term liquidity ratios indicate substantial balance-sheet coverage. The cash balance has moved within a relatively narrow band across the reported window despite volatile operating cash flow, which reduces near-term financing pressure but does not resolve the earnings problem.
Cash generation is uneven, with strong inflow periods interrupted by sizable outflows. The specific operating risk is a sustained gap between premium rates and medical claims, especially in Medicaid, because the largest revenue segment depends on state rate actions that may lag observed care costs. Marketplace losses add another route by which revenue can fail to translate into profit.
Data-derived red flags
- Negative return on equity (-0.2%) — the business is not currently generating profit on shareholder capital.
- Rich valuation — a P/E of 62.37 runs well above the Healthcare sector’s ~21.90x, leaving little room for a miss.
How much cash does the business generate or use?
Quarterly operating cash flow shows cash generated or used by operations.
- Latest quarter · operating cash flow
- −$159.00M Sep 30, 2026
- Previous quarter · operating cash flow
- −$294.00M Jun 30, 2026
| Period end | Operating cash flow | Capital expenditure (reported) |
|---|---|---|
| Sep 30, 2026 | −$159.00M | −$37.00M |
| Jun 30, 2026 | −$294.00M | −$30.00M |
| Mar 31, 2026 | $1.08B | −$27.00M |
| Dec 31, 2025 | −$298.00M | $1.00M |
Operating cash-flow bars share one scale and show magnitude; negative values mean cash used.
USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway.
What should you watch next at Molina Healthcare (MOH)?
Short answer · as of
The next earnings report is expected on Feb 4, 2027.
Research dated 2026-09-13.
Watch Medicaid profitability against management’s trough narrative. Evidence of repair would be stronger operating income and net income without reliance on a surge in operating cash flow from a particular reporting period; continued thin margins despite stable premium revenue would weaken that narrative.
Marketplace results deserve separate attention because management still expects a loss there. The scheduled earnings release also provides a direct check on whether revenue remains near current expectations while earnings begin to recover, and longer-range estimates show that analysts already assume substantial improvement.
Membership and premium-revenue guidance should be read alongside margin performance. Holding volume while medical costs remain poorly matched by rates preserves scale but not necessarily economic value.
What management is planning
Management expectations, not completed milestones or guarantees. Selected verbatim excerpts; dates follow the transcript provider.
We continue to expect full year premium revenue of approximately $42 billion.
Mark Keim ·
We expect the fourth quarter G&A ratio to fall below 6% due to the impact of operating leverage on the additional Florida CMS revenue and disciplined cost management.
Mark Keim ·
At the segment level, we expect fourth quarter Medicaid MCR of 93.6%, and the full year MCR guidance of 92.9% is unchanged.
Mark Keim ·
In Medicare, we expect fourth quarter MCR of 94.7%, and the full year MCR guidance remains at 92.2%.
Mark Keim ·
How does Molina Healthcare compare with its peers?
Short answer
Molina Healthcare's score ranks 12th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-13.
Among health-plan businesses, Molina is distinguished by its concentration in government-sponsored populations rather than a broad employer-sponsored mix. Medicaid Solutions supplies the overwhelming share of segment revenue, making state reimbursement cycles and the medical-cost experience of Medicaid members unusually important to consolidated results.
Medicare and Marketplace diversify the premium base, but neither currently changes the core exposure. Marketplace can create its own underwriting drag, while Medicare remains materially smaller than Medicaid Solutions. The useful comparison is therefore not revenue scale alone, but how effectively each managed-care operator aligns regulated premiums with claims costs across its membership mix.
| Company | Price | Market value | Score |
|---|---|---|---|
| $81.41 Oct 23, 2026 | $10.9B | 96 5-pillar Oct 26, 2026 | |
| $30.99 Oct 23, 2026 | $8.03B | 94 5-pillar Oct 26, 2026 | |
| $439.95 Oct 23, 2026 | $95.4B | 89 5-pillar Oct 26, 2026 | |
| $8.06 Oct 23, 2026 | $1.67B | 84 5-pillar Oct 26, 2026 | |
| $306.95 Oct 23, 2026 | $81.1B | 83 5-pillar Oct 26, 2026 | |
| $126.55 Oct 23, 2026 | $8.05B | 77 5-pillar Oct 26, 2026 | |
| $418.09 Oct 23, 2026 | $375B | 77 5-pillar Oct 26, 2026 | |
| $183.64 Oct 23, 2026 | $11.7B | 76 5-pillar Oct 26, 2026 | |
| $70.17 Oct 23, 2026 | $34.7B | 74 5-pillar Oct 26, 2026 | |
| $84.96 Oct 23, 2026 | $9.47B | 73 5-pillar Oct 26, 2026 | |
| $93.47 Oct 23, 2026 | $120B | 70 5-pillar Oct 26, 2026 | |
| Molina Healthcare (MOH) — this page | $209.15 | $10.9B | 66 |
| $422.07 Oct 23, 2026 | $50.7B | 55 5-pillar Oct 26, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $167.00 – $286.00
- Consensus target
- $222.10
- Median target
- $221.00
Consensus record · Captured .
Measured against a quoted price of $209.15 (as of Oct 23, 2026).
Insider activity
Form 4 records via FMP · Of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026
- Transactions
- 25
- Identified insiders
- 13
- Purchases
- 0
- Sales
- 2
- Other transactions
- 23
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
- Reporting holders
- 634 Period end Jun 30, 2026
- Previous quarter · holders
- 555 Prior to period end Jun 30, 2026
| Holders in provider snapshot | Shares |
|---|---|
| Blackrock, INC. | 6,572,156 |
| Aqr Capital Management LLC | 3,560,601 |
| Vanguard Portfolio Management LLC | 2,790,243 |
| Capital World Investors | 2,562,913 |
| Lingotto Investment Management Llp | 2,511,490 |
Quarterly filings lag the period end. Holder rows are names in the provider snapshot, not a verified ranking; individual filing dates are not supplied. Related managers may appear separately, so these positions are not summed. Holder snapshot as of Jun 30, 2026.
What has been published about Molina Healthcare (MOH)?
Common Questions About MOH (Healthcare)
Research dated 2026-09-13; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
Why can Molina Healthcare revenue rise while profit falls?
Premium volume can expand while medical claims and administrative costs consume more of that revenue. Molina’s recent record shows rising annual revenue alongside sharply weaker net income, with Medicaid rate adequacy and Marketplace losses central to the gap.
Why does Medicaid rate setting matter so much to Molina Healthcare?
Medicaid Solutions produces most of Molina’s segment revenue, while state actuaries influence the premium rates paid for covered members. Management expects future rate setting to absorb more recent medical-cost experience, so the timing and adequacy of that adjustment are crucial to margin recovery.
Is Molina Healthcare’s Marketplace business helping earnings?
Management’s outlook still calls for a full-year Marketplace loss. The segment adds premium revenue and membership exposure, but its current contribution cannot be judged by revenue alone while underwriting remains negative.
What do recent Molina Healthcare insider transactions show?
Recent insider activity shows net share sales and no purchases, while most recorded transactions were awards or an in-kind transaction. Those records describe transaction type and direction, not the reason behind an insider’s decision.
What is the MOH stock price today?
The last price recorded on this page for Molina Healthcare, Inc. (MOH) is $209.15, as of the Oct 23, 2026 trading session (source: Financial Modeling Prep (FMP) · quote). It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the MOH price target?
The analyst consensus price target for Molina Healthcare, Inc. (MOH) is $222.10 (range $167.00 to $286.00, median $221.00), per FMP data captured Oct 26, 2026. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Research written by Codex (gpt-5.6-sol) on 2026-09-13. AI-authored analysis; source dates are shown with each answer. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources — records for every figure on this page (78 figures)
The 78 rows below are exactly the facts the evidence-backed sections of this page printed — the 10-second verdict, the MoonshotScore, price and market value, the five questions with their receipts, and the records behind this page. Known dates and sources are recorded on their own rows; an em dash or UNRECORDED tier preserves a stored observation without inventing either. The quarterly income statement is provider-standardized (FMP) under one row, and scale definitions — a 0-100 rating, the band ladder, the Piotroski 0–9 range — are fixed rather than measured. No number in those sections was generated by a model. The register does not cover quoted third-party headlines, the dated council readings, or the Frequently Asked Questions; each of those says where it came from where it stands.
"As of" is the date the value is true for where the source carries one — a quarter end, a filing date, a price close, the day the score was computed. A cached observation with no source date remains undated; the page publication date is not used as a substitute.
OFFICIAL — 2 facts from SEC filings and earnings calls
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
prod.outlook | Management outlook — call excerpts | Mark Keim (Oct 22, 2026): We continue to expect full year premium revenue of approximately $42 billion. Mark Keim (Oct 22, 2026): We expect the fourth quarter G&A ratio to fall below 6% due to the impact of operating leverage on the additional Florida CMS revenue and disciplined cost management. Mark Keim (Oct 22, 2026): At the segment level, we expect fourth quarter Medicaid MCR of 93.6%, and the full year MCR guidance of 92.9% is unchanged. Mark Keim (Oct 22, 2026): In Medicare, we expect fourth quarter MCR of 94.7%, and the full year MCR guidance remains at 92.2%. | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) — Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | |
id.hq | SEC filing business address | 200 Oceangate, Suite 100, Long Beach, CA, 90802 | OFFICIAL | SEC EDGAR filer business address — The SEC filer business address. Our market-data provider separately lists "200 Oceangate, Long Beach, CA, 90802, US". |
FMP — 68 facts from Financial Modeling Prep endpoint families
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.next | Next earnings date | Feb 4, 2027 | FMP | Financial Modeling Prep (FMP) earnings calendar — The date is our provider's estimate until the company confirms it. | |
px.last | Latest provided price | $209.15 | FMP | Financial Modeling Prep (FMP) · quote — Dated to the US trading session the price belongs to, derived from the quote record's timestamp (weekend and pre-open reads roll back to the previous weekday; exchange holidays are not modelled). The record does not establish an exchange execution time. Retrieved 2026-10-26T06:34:31.759Z. | |
px.change | Change on the day | -3.46% | FMP | Financial Modeling Prep (FMP) · quote | |
px.mcap | Market capitalisation | $10.9B | FMP | Financial Modeling Prep (FMP) · quote — Date unknown Market cap record date: 2026-10-23. FMP quote timestamp: 2026-10-23T20:00:02.000Z. Captured from FMP at 2026-10-26T06:34:30.213Z. No share-count basis is inferred; this page preserves the reported amount instead of recalculating it from shares. | |
px.change_abs | Change on the day, in dollars | −$7.49 | FMP | Financial Modeling Prep (FMP) · quote | |
fin.q_revenue | Revenue, Q3 FY2026 | $10.58B | FMP | Financial Modeling Prep (FMP) · income statement (quarterly) | |
px.range52 | 52-week range | $121.06–$244.89 | FMP | Financial Modeling Prep (FMP) quote | |
px.pe | Price / earnings (trailing) | 62.37 | FMP | Financial Modeling Prep (FMP) · quote | |
px.volume | Shares traded on the day | 1.27M | FMP | Financial Modeling Prep (FMP) · quote | |
px.beta | Beta | 0.78 | FMP | Financial Modeling Prep (FMP) company profile | |
id.ceo | Chief executive | Joseph Michael Zubretsky | FMP | Financial Modeling Prep (FMP) key executives (proxy-derived) — Titles and pay come from the company's proxy statement as our provider parsed it. | |
id.employees | Employees | 19,000 | FMP | Financial Modeling Prep (FMP) employee count, from the company's filing | |
fin.annual | Revenue and net result by fiscal year | 5 fiscal years, FY2021 through FY2025: FY2021 revenue $27.77B, net result $659.00M; FY2022 revenue $31.97B, net result $792.00M; FY2023 revenue $34.07B, net result $1.09B; FY2024 revenue $40.65B, net result $1.18B; FY2025 revenue $45.43B, net result $472.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements | |
fin.rev_mix | Reported revenue segments | Medicare $6.24B · Marketplace $4.49B · Other Segments $177.00M · Medicaid Solutions Segment $32.24B | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K | |
fin.gross_margin | Gross margin (trailing twelve months) | 8.1% | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.q_table.depth.2026-09-30.revenue_k | Revenue — period end 2026-09-30 | $10.58B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-09-30.sga_k | SG&A — period end 2026-09-30 | $710.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-09-30.operating_result_k | FMP standardized operating result — period end 2026-09-30 | $106.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.revenue_k | Revenue — period end 2026-06-30 | $10.87B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.sga_k | SG&A — period end 2026-06-30 | $724.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-06-30.operating_result_k | FMP standardized operating result — period end 2026-06-30 | $145.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.revenue_k | Revenue — period end 2026-03-31 | $10.80B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.sga_k | SG&A — period end 2026-03-31 | $779.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2026-03-31.operating_result_k | FMP standardized operating result — period end 2026-03-31 | $83.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.revenue_k | Revenue — period end 2025-12-31 | $11.38B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.sga_k | SG&A — period end 2025-12-31 | $795.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
fin.q_table.depth.2025-12-31.operating_result_k | FMP standardized operating result — period end 2025-12-31 | −$162.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements — Quarterly statement note |
earn.history.depth.2026-10-21.revenue_actual | Revenue · reported — report date 2026-10-21 | $11.08B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-10-21.revenue_estimated | Revenue · estimate — report date 2026-10-21 | $10.86B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-10-21.eps_actual | EPS · reported — report date 2026-10-21 | $0.8900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-10-21.eps_estimated | EPS · estimate — report date 2026-10-21 | $0.7900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.revenue_actual | Revenue · reported — report date 2026-07-22 | $10.87B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.revenue_estimated | Revenue · estimate — report date 2026-07-22 | $10.83B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.eps_actual | EPS · reported — report date 2026-07-22 | $1.5100 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-07-22.eps_estimated | EPS · estimate — report date 2026-07-22 | $1.3900 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.revenue_actual | Revenue · reported — report date 2026-04-22 | $10.80B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.revenue_estimated | Revenue · estimate — report date 2026-04-22 | $10.87B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.eps_actual | EPS · reported — report date 2026-04-22 | $2.3500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-04-22.eps_estimated | EPS · estimate — report date 2026-04-22 | $1.9000 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_actual | Revenue · reported — report date 2026-02-05 | $11.38B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.revenue_estimated | Revenue · estimate — report date 2026-02-05 | $10.88B | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_actual | EPS · reported — report date 2026-02-05 | −$2.7500 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
earn.history.depth.2026-02-05.eps_estimated | EPS · estimate — report date 2026-02-05 | $0.4300 | Report date · | FMP | Financial Modeling Prep (FMP) earnings — Earnings-history note |
fin.q_table | Quarterly income statement | 4 quarters through Q3 FY2026 | FMP | Financial Modeling Prep (FMP) · income statement (quarterly), as filed | |
fin.cash_investments | Cash and short-term investments | $8.58B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. | |
fin.opcf_latest | Latest-quarter operating cash flow | −$159.00M | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Period end: 2026-09-30. Negative operating cash flow means cash used. This figure is not a cash-runway estimate. | |
fin.long_term_investments | Long-term investments (classification unverified) | $345.00M | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.total_debt | Total debt | $3.95B | FMP | Financial Modeling Prep (FMP), from the company's balance sheet — Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | |
fin.price_to_book | Price to book value | 2.59× | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm — A ratio our provider could not compute is absent rather than shown as zero. | |
fin.opcf.depth.2026-09-30.operating_cash_flow_m | Operating cash flow — period end 2026-09-30 | −$159.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.operating_cash_flow_m | Operating cash flow — period end 2026-06-30 | −$294.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-09-30.capex_m | Capital expenditure (reported) — period end 2026-09-30 | −$37.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-06-30.capex_m | Capital expenditure (reported) — period end 2026-06-30 | −$30.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.operating_cash_flow_m | Operating cash flow — period end 2026-03-31 | $1.08B | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2026-03-31.capex_m | Capital expenditure (reported) — period end 2026-03-31 | −$27.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.operating_cash_flow_m | Operating cash flow — period end 2025-12-31 | −$298.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
fin.opcf.depth.2025-12-31.capex_m | Capital expenditure (reported) — period end 2025-12-31 | $1.00M | Period end · | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements — Cash-flow note |
earn.pt_range | Analyst price target, low to high | $167.00 – $286.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_consensus | Consensus analyst price target | $222.10 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
earn.pt_median | Median analyst price target | $221.00 | FMP | Financial Modeling Prep (FMP) · price-target consensus — Captured Oct 26, 2026 · Coverage not supplied | |
own.insiders | Insider transactions via FMP | 25 transactions · 0 purchases, 2 sales, 23 other transactions · 13 identified insiders · of the newest 60 records, those within the last 180 days, newest dated Oct 1, 2026 | FMP | Financial Modeling Prep (FMP), carrying Form 4 transaction records — Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent. | |
own.institutions.depth.holders | Reporting holders | 634 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Period end Jun 30, 2026 | |
own.institutions.depth.holders_previous_quarter | Previous quarter · holders | 555 | FMP | Financial Modeling Prep (FMP) institutional ownership summary, from 13F filings — 13F filings are quarterly and lag the quarter end by up to 45 days. Prior to period end Jun 30, 2026 | |
own.top_holders.depth.holder_0.shares | Blackrock, INC. — shares in provider snapshot | 6,572,156 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_1.shares | Aqr Capital Management LLC — shares in provider snapshot | 3,560,601 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_2.shares | Vanguard Portfolio Management LLC — shares in provider snapshot | 2,790,243 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_3.shares | Capital World Investors — shares in provider snapshot | 2,562,913 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. | |
own.top_holders.depth.holder_4.shares | Lingotto Investment Management Llp — shares in provider snapshot | 2,511,490 | FMP | Financial Modeling Prep (FMP) institutional holders, from 13F filings — Provider snapshot as of 2026-06-30; individual filing date not supplied. |
UNRECORDED — 3 facts from stored observations whose source was not recorded
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
earn.history | Reported versus estimated, recent quarters | EPS beat 4 of 8 | UNRECORDED | Stored earnings-history observation — Captured 2026-10-23 · Expired observation | |
fin.scores | Distress and quality screens | Altman Z 4.12 · Piotroski F 5 | UNRECORDED | Stored financial-scores observation — Captured 2026-10-24 · Expired observation | |
fin.ratios | Return and yield ratios (trailing twelve months) | ROE -0.2% · ROA -0.0% · current ratio 1.68 · earnings yield -0.1% · free-cash-flow yield 2.5% | — | UNRECORDED | Stored key metrics — Date unknown |
COMPUTED — 3 facts from our arithmetic, formula restated
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
fin.mcap_to_cash | Market value per dollar of cash and short-term investments | 1.27× | — | COMPUTED | Computed on this page from the figures above — The market capitalisation printed on this page divided by cash and short-term investments of $8.58B at Sep 30, 2026. Long-term investments are excluded and remain unclassified. Restrictions on cash and short-term investments require separate review. Market cap record date: 2026-10-23. Balance-sheet reference date: 2026-09-30. The inputs do not establish a single common source date for this ratio. |
earn.history.depth.2026-10-21.revenue_actual.comparison | Latest report · revenue vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported revenue ($11.08B) with the recorded estimate ($10.86B) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
earn.history.depth.2026-10-21.eps_actual.comparison | Latest report · EPS vs estimate | Above estimate | Report date · | COMPUTED | Computed from Financial Modeling Prep (FMP) earnings — Earnings-history note — Method: compare reported EPS ($0.8900) with the recorded estimate ($0.7900) at displayed precision. Equal displayed values are in line. This compares reported results with recorded estimates, not investment returns. |
OURS — 2 facts from Stock Expert AI's own score and rank
| Fact ID | Fact | Value as shown | As of | Tier | Source |
|---|---|---|---|---|---|
ours.moonshot | MoonshotScore v2 | 66 of 100 · Strong · pillars 70 / 38 / 77 / 36 / 80 | OURS | Stock Expert AI MoonshotScore v2 engine | |
ours.moonshot_change | MoonshotScore movement | 65 (stored snapshot Oct 24, 2026) → 66 (current publication computed Oct 26, 2026) (+1) | OURS | Stock Expert AI current score publication and immutable score snapshots |
Fact-family notes
- Quarterly statement note. Source series as of 2026-09-30. USD. The operating result is the FMP-standardized value supplied by FMP; it may differ from a filing’s GAAP loss from operations when the provider classifies separately presented items differently. It is not net income or cash flow. Applies to Fact IDs:
fin.q_table.depth.2026-09-30.revenue_k,fin.q_table.depth.2026-09-30.sga_k,fin.q_table.depth.2026-09-30.operating_result_k,fin.q_table.depth.2026-06-30.revenue_k,fin.q_table.depth.2026-06-30.sga_k,fin.q_table.depth.2026-06-30.operating_result_k,fin.q_table.depth.2026-03-31.revenue_k,fin.q_table.depth.2026-03-31.sga_k,fin.q_table.depth.2026-03-31.operating_result_k,fin.q_table.depth.2025-12-31.revenue_k,fin.q_table.depth.2025-12-31.sga_k,fin.q_table.depth.2025-12-31.operating_result_k. - Earnings-history note. Source series as of 2026-10-21. Dates are report dates, not fiscal period ends. Revenue is in USD; EPS is USD per share, rounded to four decimals. The earnings feed does not establish a basic, diluted or adjusted basis. Earnings-feed EPS may differ from statement EPS; the two series are not combined. Applies to Fact IDs:
earn.history.depth.2026-10-21.revenue_actual,earn.history.depth.2026-10-21.revenue_estimated,earn.history.depth.2026-10-21.revenue_actual.comparison,earn.history.depth.2026-10-21.eps_actual.comparison,earn.history.depth.2026-10-21.eps_actual,earn.history.depth.2026-10-21.eps_estimated,earn.history.depth.2026-07-22.revenue_actual,earn.history.depth.2026-07-22.revenue_estimated,earn.history.depth.2026-07-22.eps_actual,earn.history.depth.2026-07-22.eps_estimated,earn.history.depth.2026-04-22.revenue_actual,earn.history.depth.2026-04-22.revenue_estimated,earn.history.depth.2026-04-22.eps_actual,earn.history.depth.2026-04-22.eps_estimated,earn.history.depth.2026-02-05.revenue_actual,earn.history.depth.2026-02-05.revenue_estimated,earn.history.depth.2026-02-05.eps_actual,earn.history.depth.2026-02-05.eps_estimated. - Cash-flow note. Source series as of 2026-09-30. USD. Negative operating cash flow means cash used. Capital expenditure keeps the provider’s reported sign; it is not added here to estimate free cash flow or runway. Applies to Fact IDs:
fin.opcf.depth.2026-09-30.operating_cash_flow_m,fin.opcf.depth.2026-06-30.operating_cash_flow_m,fin.opcf.depth.2026-09-30.capex_m,fin.opcf.depth.2026-06-30.capex_m,fin.opcf.depth.2026-03-31.operating_cash_flow_m,fin.opcf.depth.2026-03-31.capex_m,fin.opcf.depth.2025-12-31.operating_cash_flow_m,fin.opcf.depth.2025-12-31.capex_m.
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources used for research written 2026-09-13
Historical evidence preserved with this analysis. Current figures are listed separately above.
| Evidence | Captured value | Source date | Source type | Source |
|---|---|---|---|---|
| Legal name | MOLINA HEALTHCARE, INC. Our market-data provider lists the name as "Molina Healthcare, Inc."; the filer's own record is used here. | 2026-02-10 | OFFICIAL | SEC EDGAR — 10-K filed 2026-02-10 |
| Business description | Molina Healthcare, Inc. offers comprehensive managed health care services, primarily targeting economically disadvantaged families and individuals. The company provides coverage through key government initiatives such as Medicaid and Medicare programs, in addition to state health insurance marketplaces. Its operations are strategically segmented into four main divisions: Medicaid, Medicare, Marketplace, and a general "Other" category. By the close of 2021, specifically December 31st, Molina Healthcare's network extended to approximately 5.2 million members across 18 states, all of whom qualified for Medicaid, Medicare, or other government-sponsored healthcare plans. Established in 1980, the company maintains its corporate headquarters in Long Beach, California. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Revenue by segment | Medicare: $6.24B; Marketplace: $4.49B; Other Segments: $177.00M; Medicaid Solutions Segment: $32.24B | 2025-12-31 | FMP | Financial Modeling Prep (FMP) revenue segmentation, from the company's 10-K |
| Management outlook — dated call excerpts | Captured record · 4 entries
Selected verbatim statements from the latest available call, dated by the transcript provider. Management expectations, not completed milestones or guarantees. Relative dates retain the speaker's wording. | 2026-07-23 | OFFICIAL | Company earnings call, transcript via Financial Modeling Prep (FMP) |
| Annual revenue and net result (USD millions) | Captured record · 5 entries
| 2025-12-31 | FMP | Financial Modeling Prep (FMP), from the company's 10-K income statements |
| Quarterly income statement (USD thousands) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q and 10-K income statements |
| Trailing twelve-month ratio set | Quick ratio: 1.68; Current ratio: 1.68; Debt to equity: 0.95; Net margin: 0%; Gross margin: 34.6%; Operating margin: 0.7%; Return on assets: 0%; Return on equity: -0.2% Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. A ratio our provider could not compute is absent rather than shown as zero. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) key-metrics-ttm + ratios-ttm |
| Reported versus estimated, last 8 quarters | Captured record · 8 entries
| 2026-07-22 | FMP | Financial Modeling Prep (FMP) earnings |
| Most recent periodic reports | 2026-07-23 | OFFICIAL | SEC EDGAR filer submissions | |
| Cash, investments and debt | Total debt: $3.95B; Liquidity basis: cash and short-term investments; Total liabilities: $11.83B; Cash and short-term investments: $8.91B; Cash and investments: $9.23B; Long-term investments: $313.00M; Long-term investments classification: unclassified Long-term investments are shown separately; their marketability is not established by the provider field. The cash and short-term investment balance does not establish unrestricted availability. | 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's balance sheet |
| Cash and investment components | Total basis: cash short and long-term investments; Total: $9.23B; Cash and short-term investments: $8.91B; Long-term investments: $313.00M; Long-term investments classification: unclassified Sums the balance sheet's cash and short-term investments with its long-term investments.; The long-term investment field does not establish marketability; the sum is not a measure of available liquidity.; These provider fields do not establish investment access restrictions or explain differences from third-party cash figures. | 2026-06-30 | COMPUTED | Computed from the balance sheet |
| Cash and short-term investments over time (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's quarterly balance sheets |
| Cash decline over the reported window | To: 2026-06-30; From: 2024-09-30; Periods: 7; Cash basis: cash and short-term investments; Closing balance: $8.91B; Decline: $299.00M; Opening balance: $9.21B; Average change per period: $42.70M Change in cash, cash equivalents and short-term investments between the 2024-09-30 and 2026-06-30 balance sheets.; This is a balance change, not operating burn: financing and investing move it too.; Averaged over 7 reporting periods of unequal length. | 2026-06-30 | COMPUTED | Computed from reported balances |
| Cash against market value | As of: 2026-06-30; Cash basis: cash and short-term investments; Net cash: $4.96B; Total debt: $3.95B; Cash and investments: $8.91B Price-based multiples captured at research time are not repeated here; the page shows each once, from current figures with their own dates. Cash is the latest reported cash and short-term investment balance; long-term investments are excluded. Market capitalization is the latest provider value.; The reported balance does not establish unrestricted availability or liquidation value.; The two are measured on different dates — the balance sheet is a quarter-end, the market cap is a recent close.; Debt is total debt as reported, including operating lease liabilities where the filer includes them. | 2026-06-30 | COMPUTED | Computed from the balance sheet and the latest market capitalization |
| Operating cash flow by quarter (USD millions) | Captured record · 8 entries
| 2026-06-30 | FMP | Financial Modeling Prep (FMP), from the company's 10-Q cash-flow statements |
| Distress and quality screens | Altman Z-score: 4.08; Piotroski F-score: 6 Altman Z below 1.8 is the conventional distress zone. The screen is built for manufacturers and industrials; for banks, insurers and property companies it is not a meaningful reading. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) financial scores |
| Next earnings report | Date: 2026-10-21; EPS estimate: $0.823 per share; Revenue estimate: $10.86B The date is our provider's estimate until the company confirms it. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) earnings calendar |
| Analyst revenue and earnings estimates (average) | Captured record · 4 entries
| 2026-09-13 | FMP | Financial Modeling Prep (FMP) analyst estimates |
| Sector / industry (provider taxonomy) | Healthcare / Medical - Healthcare Plans The company's SEC filings classify it under SIC 6324 — Hospital & Medical Service Plans. | 2026-09-13 | FMP | Financial Modeling Prep (FMP) company profile |
| Insider transactions, last 180 days | Net shares: -12,746; Window days: 180; Price low: $135.82; Clustered days: 2026-04-01; 2026-06-30; 2026-07-01; Price high: $232.55; Buy transactions: 0; Distinct insiders: 13; Sell transactions: 2; Other transactions: 22; Total transactions: 24; Other transaction types: A-Award: 21, F-InKind: 1; Unknown direction transactions: 0 Purchase and sale counts require explicit provider transaction types, without a conflicting acquisition/disposition direction. Other transactions retain their provider type; awards, exercises, gifts and in-kind transactions are not counted as purchases or sales. Net shares sums acquired minus disposed shares across direction-known records, including other transaction types; unknown directions are excluded. It is not net purchases or a verified change in beneficial ownership. Named-insider counts, same-day clusters and positive reported prices cover all retained records. Filing dates are used only when transaction dates are absent. Neither timing nor price establishes motive or whether a transaction was on the open market. | 2026-07-01 | FMP | Financial Modeling Prep (FMP) insider transactions, from Form 4 filings |
Data provided for informational purposes only.
ETFs that hold MOH
Funds in our ETF coverage that list MOH among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| SOVF ETF | 3.95% | |
| DWSH ETF | 1.08% |